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Precis: This study evaluates the drivers of spending variation in the treatment of 
localized prostate cancer and found that the highest spending urologists and radiation 
oncologists spent 46% and 43%, respectively, more than the lowest on men with similar 
individual and disease characteristics; across facilities, this difference was 36% and 48% 
for urology and radiation oncology, respectively. Differences in primary treatment 
modalities and discretionary decision-making for similar patients were the most 
important drivers of spending variation, and to improve value, interventions should target 
decision-making along the primary treatment pathway and be directed at both individual 
physicians and facilities.
Abstract 
Background: Prostate cancer is the most common male cancer with a wide range of 
treatment options. Payment reform to reduce unnecessary spending variation is an 
important strategy to reduce waste, but its magnitude and drivers within prostate cancer 
are unknown. 
Subjects: 38,971 men ≥ 66 years with localized prostate cancer enrolled in Medicare fee-
for service and contained within the Surveillance, Epidemiology, and End Results-
Medicare 2009-2014 database.
Methods: Using multi-level linear regression with physician and facility random effects, 
we examined the contributions of urologists, radiation oncologists, and their affiliated 
facilities to variation in total patient spending in the year following diagnosis within 
geographic region. We assessed whether spending variation was driven by patient 
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quintiles of adjusted patient-level spending, and differences between those that were 
high- and low-spending were examined.
Results: Substantial variation in spending was driven by physician and facility factors. 
Differences in cancer treatment modalities drove more variation across physicians than 
differences in patient and disease characteristics (72% vs 2% for urologists, 20% vs 18% 
for radiation oncologists). The highest-spending physicians spent 46% more than the 
lowest and had more imaging tests, inpatient care, and radiotherapy spending. There were 
no differences across spending quintiles in utilization of robotic surgery by urologists or 
brachytherapy by radiation oncologists.
Conclusions: Significant differences were observed for patients with similar 
demographics and disease characteristics. This variation across both physicians and 
facilities suggests that efforts to reduce unnecessary spending must address decision-
making at both levels. 
Keywords: prostate cancer, cancer cost of care, health economics, health services 
research, practice variation
Total Numbers: 1) 23 text pages and 45 references, 2) three tables, 3) two figures, 4) 
nine supporting files
INTRODUCTION
Prostate cancer is the most common cancer among men in the United States (US), 
with more than 160,000 men diagnosed in 2017.1 The cost of caring for these affected 
individuals is correspondingly large, with an estimated $11.85 billion spent in the US in 
2010 and a nearly 20% increase projected by 2020.2 Benchmarks for appropriate 
spending have been difficult to establish because of the range of treatment options 
available and the introduction of novel and expensive technologies over the last decade, 
which vary widely in their costs and clinical appropriateness.3-6 However, a large body of 
research, including in oncology, has demonstrated that significant differences in health 
care spending across and within geographic regions are not necessarily associated with 
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To reduce inappropriate variation in care and its associated costs, payers and 
oncology professional associations are spearheading payment reform efforts that include 
hybrid systems of bundled and episode-based payments, with some pay-for-performance 
metrics.11, 12 Medicare’s new Merit-Based Incentive Payment System (MIPS) evaluates 
total spending and will implement both financial penalties and rewards based on 
adherence to specific practice patterns. With more than 60% of prostate cancer cases 
diagnosed in individuals over the age of 65,13 initiatives to reduce low-value prostate 
cancer care in Medicare could have significant impact on public resource use and 
spending. Determining sources and drivers of variation in prostate cancer spending will 
be more important to identify opportunities for intervention to reduce inefficiencies and 
overuse and to ensure the delivery of value-based care under these new payment 
methods. 
There is a growing body of evidence examining the association of patient and 
provider factors with choice of treatment in prostate cancer.14-16 However, the 
contribution of physicians and facilities to variation in overall spending within 
geographic regions, and whether this variation is related to differences in clinical 
presentations and comorbidities or due to other factors, is unknown. To bring evidence to 
bear on this question, we analyzed variation in medical spending within geographic 
regions during the first year following the diagnosis of locoregional prostate cancer, 
which is the primary decision-making period for most patients.17 We focused on variation 
within, rather than across, geographic regions to elucidate heterogeneity in practice 
within these regions, which would not be due to variation in reimbursement levels or 
regional practice patterns. We examined the extent to which differences across facilities 
and across physicians within facilities contributed to spending variation and quantified 
the proportion of physician and facility variation that could be explained by differences in 
patient characteristics, disease risk, the treatment modalities provided, or by other 
discretionary management decisions. 
MATERIALS AND METHODS
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We analyzed the Surveillance, Epidemiology, and End Results (SEER)-Medicare 
database, which includes cancer registries from 18 catchment areas across the US 
covering approximately 34% of the population linked to Medicare claims.18 Our data 
included men enrolled in fee-for-service Medicare diagnosed with locoregional prostate 
cancer in 2010-2013, with corresponding medical claims for 2009-2014. 
 We excluded 65-year old men because they did not have prior year medical 
claims data to measure baseline health status. Patients with the following characteristics 
were also excluded: metastatic disease; a prior or synchronous cancer diagnosis, as their 
care needs are significantly different; death within one year of diagnosis; missing data on 
key study variables; lack of continuous coverage of Medicare Part B; or no claims with a 
urologist or a radiation oncologist. Patients diagnosed with a second malignancy in the 
same month as their prostate cancer diagnosis were excluded. If another cancer was 
diagnosed after the first full-month, patients would be included in the analysis until the 
time of the second malignancy diagnosis. Analyses could not be performed on patients 
living in a Hospital Referral Region (HRR) with fewer than 10 patients due to 
computational limitations, so these patients were also excluded. The final sample 
included 35,545 men (see Supplemental Digital Content 1 for full sample construction). 
Variables and Outcomes
Unadjusted monthly spending was estimated for all patients. The dependent 
variable in the analyses was total annual medical spending per patient, excluding 
outpatient pharmacy (Part D). We defined three categories of independent variables: (1) 
patient and disease characteristics, (2) patient receipt of treatment modalities, and (3) 
attributed physician and facility. Patient and disease characteristics included: age; race; 
health status measured using the Charlson comorbidity index with Klabunde 
modification19 based on the year prior to diagnosis; original reason for Medicare 
eligibility; dual enrollment in Medicaid; enrollment in a Part D plan; average income 
based on census tract residence; census tract education (proportion with some college or 
above); and prostate cancer risk group, defined using the National Comprehensive Cancer 
Network (NCCN) criteria20 on T-stage, Gleason score, and PSA, which is the 
classification system primarily used to drive decision-making amongst urologists and 
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due to the absence of information on PSA density and number of positive cores. Patients 
were classified as very high-risk based on T-stage and Gleason Score.
Treatment modalities were measured as binary indicators of whether or not the 
patient was treated with: active surveillance or watchful waiting (AS/WW) (defined as no 
treatment 6 months after diagnosis); surgery (open prostatectomy, minimally invasive 
prostatectomy [with or without robotic assistance], or cryosurgery); radiation (external 
beam radiation therapy [EBRT] and brachytherapy); and hormone therapy. AA and WW 
were grouped together because of the difficulty in accurately distinguishing them within 
the data21 and because spending using previously published definitions22 was observed to 
be similar in preliminary analyses.
Attribution
First, we attributed all patients to the urologist providing the plurality of their 
care. Patients with at least one visit with a radiation oncologist (RO) were also attributed 
to the RO associated with the greatest number of their medical claims. We then attributed 
patients to facilities according to the plurality of their attributed physicians’ billings. 
Thus, even if a physician practiced at multiple facilities, patients were attributed to the 
facility where the plurality of claims were made. Patients attributed to a urologist and an 
RO could be attributed to two different facilities (57% of patients). While the availability 
of specific technology and services may drive treatment choices and spending across 
facilities,23-25 understanding variation within facilities facilitates an understanding of the 
effect that local practice patterns may have on physicians who work together.  
Variation across Physicians and Facilities
To determine the contribution of physician and facility differences to variation in 
total spending, we estimated two sets of multi-level linear regression models that 
included physician and facility random effects, where physicians were nested within a 
facility and the unit of analysis was the patient-year. The first set of models included the 
full sample of patients and the random effects identified the patient’s attributed urologist 
and the urologist’s attributed facility. The second set of models included only patients 
who were also attributed to an RO, and the random effects identified the patients’ RO and 
the RO’s attributed facility. A sensitivity analysis was also performed of a third set of 
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time (calendar-quarter of diagnosis). and region fixed effects to evaluate variation in 
spending within geographic areas and time periods, rather than between regions and time. 
Time was measured as the quarter of diagnosis and geographic region was measured as 
the HRR within which the patient received the plurality of his care. To lessen the 
influence of outliers, all observations of spending above the 99th percentile were set to the 
value of the 99th percentile. Additional methodological details and model output is 
available in the Appendix.
We report results in three ways: (1) the percent of variation in total spending 
driven by physicians or by facilities, calculated as the physician or facility variance 
divided by the total variance in the model (total = physician + facility + residual); (2) the 
predicted additional spending for patients with physicians or facilities with spending one 
standard deviation above the mean; and (3) the difference in spending driven by this level 
of variation between “high-spending” (top 20% of spending) versus “low-spending” 
(bottom 20% of spending). We estimated models for the full patient samples and 
stratified by NCCN risk groups.20 All statistical analyses were completed using Stata 
(Version 14). 
Analysis of Drivers of Variation
We quantified the proportion of spending variation across physicians and facilities 
explained by observable differences in patient characteristics, in disease risk, or in 
provision of treatment modalities, by estimating two additional sequential models. The 
first included independent variables measuring patient and disease characteristics. The 
second added variables indicating treatment modalities. The proportion of physician and 
facility variance explained by the added variables was measured as the difference 
between the physician and facility variance with and without the additional variables 
divided by the physician and facility variance without the additional variables. Patients 
with unknown risk group and with <12 month of claims were excluded from these 
models. Model results of all excluded patients are shown in Supplemental Digital Content 
2.
Variation in Treatment Intensity by Spending Quintile
To identify other specific contributors to the variation across physicians and 
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are high- and low-spending. We used model output from the multi-level mixed regression 
models described above to estimate predicted physician and facility average per-patient 
annual spending, which was adjusted for differences in time, geography, patient 
population, disease characteristics, and for decisions to provide each of the treatment 
modalities. We then sorted physicians and facilities into quintiles according to their 
adjusted spending (1 – lowest; 5 – highest) and examined differences in utilization and 
spending outcomes between those that were “high-spending” (the top quintile according 
to adjusted spending) versus “low-spending” (the lowest adjusted quintile). An additional 
sensitivity analysis sorting physicians and facilities into quartiles of spending was 
performed. 
Using multivariate regression models, in which key independent variables were 
dummy variables indicating the spending quintile, we estimated values for each quintile 
in: average inpatient days and imaging tests per patient; likelihood of undergoing 
AS/WW; use of cryosurgery and open or robotic prostatectomy among patients 
undergoing surgery; and, among patients receiving radiation, spending on radiotherapy 
and the likelihood of receiving of brachytherapy, EBRT (3D-conformal radiotherapy), 
IMRT, stereotactic body radiation therapy (SBRT), or proton beam therapy (PBT) among 
patients receiving radiation. Logistic regression was used for all binary outcomes 
(whether a patient had a particular type of treatment) and linear regression was used for 
all continuous outcomes (inpatient days, imaging tests, and spending). All regressions 
controlled for patient and disease characteristics, treatment modalities, time and 
geography. We also tested for a linear trend in utilization and spending across quintiles. 
Standard errors were clustered on the attributed physician and facility. 
RESULTS
Unadjusted monthly spending varied considerably throughout the year across all 
risk groups, with the majority of spending in the first 6 months following diagnosis and 
very low spending in months 7-12 (Figure 1). Average spending increased with risk 
group, from $24,169 (SD $18,685) per year in very low- or low-risk patients to $32,833 
(SD $19,940) per year among very-high risk patients (p<0.001) (see Supplemental 
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presented in Table 1. A descriptive analysis of treatment choices by risk group is 
presented in Supplemental Digital Content 4.
In the multi-level models with urologist and facility random effects, 4.5% of 
variation in spending was driven by differences across urologists and 5.5% by differences 
across facilities (Table 2). For a patient with spending one SD above the mean, this level 
of variation suggests that urologists and urologist-affiliated facilities were responsible for 
$3,743 and $4,130, respectively, in above-average spending. Comparing the highest and 
lowest quintiles of spending, a patient with a high-spending urologist would have 
$11,685 higher average annual spending than if that patient had a low-spending urologist 
(39% over the mean); for urologist affiliated facilities, this variation is associated with a 
difference of $9,310 (31% over the mean). Among patients who also saw an RO, 6.1% of 
the variation in their spending was driven by differences across ROs and 5.8% by 
differences across RO facilities. This means that ROs and RO-affiliated facilities were 
responsible for $3,531 and $3,858, respectively, in above-average spending for a patient 
with spending one SD above the mean. This level of variation is also associated with a 
difference in average annual spending of $13,695 (36% over the mean) between high- 
and low-spending ROs and $14,797 (39% over the mean) between high- and low-
spending RO-affiliated facilities.  
Differences in patient characteristics and disease risk, which capture patient 
sorting across physicians (e.g. specialization of certain physicians in patients with more 
advanced disease), explained 2% of between-urologist variation and 1% of between-
facility variation; differences in the treatment modalities provided to patients explained 
72% (Figure 2). In models analyzing spending variation across ROs, patient and disease 
characteristics explained 18% of variation in spending between physicians. Differences in 
treatment modalities provided to patients with similar characteristics explained 20% of 
variation across ROs and 34% of variation across facilities. 
When models were stratified by disease risk, a greater proportion of variation was 
explained by differences across physicians and across facilities in low-risk patients (see 
Supplemental Digital Content 5 for model results by risk group). However, the 
contribution of patient, disease and treatment characteristics was similar across risk 
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and disease characteristics were responsible for a great proportion of variation across 
physicians and facilities (13% and 16%, respectively) (Supplemental Digital Content 6). 
After adjusting for the characteristics and disease risk of a physician’s patients 
and in the treatment modalities provided, the highest-spending quintile of urologists had 
46% higher annual predicted spending compared to the lowest ($36,876 vs $25,191) 
(Table 3). There was no difference across quintiles in the likelihood of their patients 
undergoing AS/WW, duration on a surveillance regimen prior to treatment, or utilization 
of robotic surgery. Differences between quintiles were observed in use of inpatient care, 
imaging investigations, and radiotherapy. Compared to urologists in the lowest-spending 
quintile, urologists in the highest-spending quintile were associated with 44% greater 
spending on radiotherapy, with an 18% increased likelihood of IMRT (p<0.001), and a 
75% increased likelihood of PBT (p<0.001). Differences between urologist spending 
quartiles and between urology facilities showed similar results. See Supplemental Digital 
Content 7 for results of physician and facility variation by quartile and Supplemental 
Digital Content 8 for results of facility variation by quintile. 
The average spending per patient associated with ROs was 43% greater in the 
highest spending quintile than the lowest quintile ($45,372 vs $31,677, p<0.001) (Table 
3), with quintile differences that were similar to those of urologists. Compared to the 
lowest quintile, ROs in the highest quintile were 25% more likely to use IMRT and six 
times more likely to use PBT (p<0.001), although overall use of PBT was low. There was 
no significant differences in AS/WW, imaging tests, or brachytherapy utilization between 
RO quintiles, although patients treated at facilities in the highest spending quintile were 
23% less likely to undergo AS/WW (p<0.001) compared to those treated at facilities in 
the lowest quintile. 
DISCUSSION
In our analysis of fee-for-service Medicare, there was wide variation in spending 
for men with locoregional prostate cancer who have similar demographics, comorbidities, 
and disease characteristics. This variation was driven by both physicians and facilities, 
and the proportion of variation that they explain is consistent with other studies of 
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study is substantial, such that the highest spending urologists had an average of 46% 
($11,685) greater spending for similar patients than the lowest-spending urologists; for 
patients who saw ROs, the difference was $13,695. 
Very little variation in spending across urologists, ROs, or their affiliated facilities 
was explained by observable differences in patient characteristics or disease severity, 
suggesting that the variation is unlikely to be due to patients with different needs 
choosing to see different providers. The variation was also not explained by differences 
in prices or reimbursement across regions of the country, as our analysis focused on 
variation within HRRs. Instead, we find that spending variation across both physicians 
and facilities was largely explained by differences in the treatment modalities used, with 
significant differences in radiotherapy spending and the use of expensive technology. 
Prior and ongoing efforts to improve care and to optimize spending have included 
reducing variability in active surveillance,28 promoting more appropriate use of 
imaging,29 and refining approaches to screening.30 There has also been evidence of 
overtreatment of men with localized disease31 and concerns about overutilization of 
IMRT among self-referring urologist groups due to the higher reimbursement rates 
compared to conventional treatment.32. While uncertainty about current best practice 
guidelines for prostate cancer may contribute to some observed variation, these findings 
suggest that there is also evidence of inappropriate spending. More recently, the 
American Society for Radiation Oncology included PBT on its Choosing Wisely list as a 
service that is high cost, but of no greater value to patients compared to other available 
technology.33,34 We found that the highest-spending physicians are associated with 
greater use of PBT, though rates of use were low overall. Moreover, the risk of 
inappropriate overuse is likely to continue to increase over time. Since 2016, large phase 
III trials have demonstrated the non-inferiority of hypofractionated radiotherapy 
compared to longer, conventionally fractionated treatment for localized disease,35-37 yet 
because a fee-for-service system links reimbursement to the number of radiation 
treatment days, we are likely to see variability in the uptake of this data. 
As Medicare continues to move away from volume-based fee-for-service and to 
link reimbursement to value-oriented targets, eligible health care providers are expected 
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organization or bundled payment.38,39 Under MIPS, physician reimbursement is tied to a 
Composite Performance Score based on four categories of performance, which include 
quality and resource use. Current prostate cancer quality indicators target use of imaging 
for low-risk patients, although our results suggest that it may also be productive to target 
variation in radiotherapy under this program. Although the continued implementation of 
this program is uncertain, the concept of value-based reimbursement has broad bipartisan 
support and is also favored by private insurers.
Although the benefit of robotics over open surgery has been questioned40 and its 
higher cost has led to debates over its funding in some jurisdictions,41 we found that the 
use of robotic surgery did not differ between high- and low-spending urologists. This 
paradox may be explained by the widespread diffusion of robotic technology in high-
volume prostatectomy centers across the US25 and suggests that payment reform will 
need to be applied equally across urologists, instead of targeting only the highest resource 
users. 
This study must be considered in the context of its strengths and limitations. The 
analysis of administrative claims that are linked with cancer registry data facilitates a 
robust evaluation of spending variation in the context of important disease-related factors. 
However, variation in treatment choices may be affected by other clinical or patient 
factors (e.g. preference for more vs. less intensive treatment) that are not captured within 
the data and that may have contributed to the unexplained variation in our analysis. We 
were also unable to control for differences in physician characteristics, which may have 
influenced treatment patterns.14-16 Our comparison of high- and low- spending physicians 
and facilities treating similar patients elucidated some of the potential sources of the 
unexplained variation, although there was a high degree of unexplained variation across 
ROs and we did not have long-term outcome data to examine whether differences in 
spending contribute to outcomes. 
Our analysis focused on elderly men with locoregional disease, which may limit 
its generalizability to younger patients and to those with metastatic disease 
(approximately 6% of new diagnoses42), who are increasingly being treated with a variety 
of new high-cost agents.43, 44 Further, although we excluded men who died within their 
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nearly 100%.42 Thus, the vast majority of men with new prostate cancer diagnoses were 
included in our sample. All patients were insured by Medicare, so drivers of variation in 
spending among other types of patients (e.g., Medicaid or commercial insurance) or those 
with incomplete Medicare Part B coverage could not be assessed. However, over 60% of 
prostate cancer patients are diagnosed at age 65 or older12 and many others will obtain 
Medicare coverage within the course of their disease. Moreover, these findings may have 
broader impact as many policy and payment structures piloted within Medicare are 
subsequently adopted by commercial insurers.45 
CONCLUSIONS
Variation in medical spending for men with similar demographics and disease risk 
in the year following the diagnosis of locoregional prostate cancer was driven by both 
physicians as was as facilities and was largely explained by differences in the primary 
treatment pathway for patients. The significant differences observed suggest that there is 
a pressing need to design interventions to improve adherence to clinical practice 
guidelines and to promote judicious use of high-cost interventions. Such interventions 
may improve the affordability and value of prostate cancer treatment. Further research is 
needed to understand in what circumstances higher spending may be associated with 
demonstrable benefit to prostate cancer patients. 
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Figure 1: Average Monthly Patient Spending in the First Year after Prostate Cancer 
Diagnosis
Source: Authors’ analysis of Surveillance, Epidemiology, and End Results (SEER)-
Medicare linked data 2009-2014. Results are stratified by National Comprehensive 
Cancer Network (NCCN) disease risk group. Very-low risk grouped with low-risk 
because of lack of PSA density data within SEER. 
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Figure 2. Factors that Explain Spending Variation Across Physicians and Facilities
Source: Authors’ analysis of Surveillance, Epidemiology, and End Results (SEER)-
Medicare linked data 2009-2014.
Note: Each bar represents the explanatory factors of that component variation in 
spending. Results based on regression models include random effects for physicians and 
patients and fixed effects for time, health referral region, disease risk group at diagnosis, 
patient characteristics, and treatments. Patient characteristics include age, race, census 
tract income, census tract education, dual eligibility, Charlson score, Part D enrollment, 
and disability. Treatments include watchful waiting or active surveillance surgery, 
radiation, hormone therapy, and chemotherapy. Spending is winsorized at the 99th 
percentile. Urology results based on model with random effects for urologist and 
urologist-affiliated facility. Radiation Oncology results based on model with random 
effects for attributed radiation oncologist and radiation oncologist-affiliated facility.
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Table 1.  Sample Characteristics 
 





Excluded Patients  
(N=6,209) 
 % N % N % N 
Age at diagnosis (mean, SD) 73.36 (5.68) 73.07 (4.98) 73.48 (5.80) 
66-75  69.2% 24,297 70.7% 14,442 69.1% 4,378 
76-85 27.3% 9,587 27.8% 5,682 26.6% 1,687 
85+  3.6% 1,249 1.4% 295 4.2% 267 
Non-white  17.3% 6,078 17.2% 3,506 17.9% 1,008 
Census tract income (mean, SD) $68,677 ($33,313) $69,736 ($33,446) $67,115.1 ($32,607) 
Census tract, % with some college education 61.2% 21,501 61.6% 12,578 61.1% (19.3%) 
Dual eligible  13.4% 4,697 12.0% 2,455 15.1% 954 
Originally eligible for Medicare based on 
disability  
7.9% 2,790 8.1% 1,653 9.5% 601 
Part D Drug coverage  50.9% 17,888 51.1% 10,437 45.4% 2,877 
Charlson score (mean, SD) 0.86 (1.29) 0.85 (1.27) 0.85 (1.36) 
0  55.0% 19,323 55.0% 11,234 58.3% 3,690 
1  23.9% 8,390 23.9% 4,890 21.0% 1,328 
2+  21.1% 7,420 21.0% 4,295 20.8% 1,314 
Stage of disease at diagnosis 
  
 
Stage 1  19.8% 6,961 19.5% 3,984 62.4% 3,953 
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Stage 2b  31.8% 11,184 28.0% 5,711 7.9% 503 
Stage 3  8.0% 2,823 7.0% 1,421 1.6% 103 




Very low or low  18.8% 6,596 19.4% 3,970 4.9% 313 
Intermediate  33.1% 11,614 35.5% 7,249 7.9% 501 
High  37.9% 13,310 35.0% 7,153 11.6% 735 
Very high 10.3% 3,613 10.0% 2,047 3.0% 193 




Watchful waiting or active surveillance 20.2% 7,089 12.2% 2,481 45.0% 2,851 
Surgery 25.0% 8,783 11.0% 2,251 22.9% 569 
Radiation 50.8% 17,864 83.5% 17,057 11.0% 1,452 
Hormone therapy 35.9% 12,628 44.4% 9,069 9.0% 696 
Source: Authors’ analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data 2009-2014.  
Note: Treatment modalities not mutually exclusive and are defined as: active surveillance or watchful waiting = no treatment 6 
months after diagnosis; surgery = open prostatectomy, minimally invasive prostatectomy [with or without robotic assistance], or 
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% Unadjusted variation 
driven by: 
 




For spending one SD 
above mean, dollars of 
spending driven by: 
 
Difference in adjusted patient 















High vs low 
spending 
physicians 

















4.9% 4.6% 5.1% 4.9% $3,828 $3,736 $11,658 $8,827 





























5.6% 5.3% 5.3% 6.2% $3,405 $3,694 $13,602 $14,057 
Source: Authors’ analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data 2009-2014. 
Note: Results are based on multi-level models with physician and facility random effects, controlling for time (quarter-calendar) and 
HRR variables. Urology results based on model with random effects for urologist and urologist-affiliated facilities. Radiation 
oncology results based on model with random effects for attributed radiation oncologist and radiation oncologist-affiliated facility. 
Spending one SD above the mean is reported as the square root of the physician and facility variance from these models, adjusted 
for patient and disease characteristics. The highest and lowest spending physicians and facilities refer to patients in the highest and 
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Table 3. Differences in Treatment Intensity across Physician Quintiles 
  
Quintiles of spending  
(1 = lowest, 5 = highest) 
 
Quintile 
1 vs 5 P-value 
  1 2 3 4 5 
 
 
Urology              
Number of providers 555 554 554 554 554 
  
Number of patients 10732 5433 3835 5906 9227 
  
  
       
Average total spending per patient per 
year ($) 
25,191 27,268 29,925 32,130 36,876 46% <0.001 
Inpatient days per year 1.29 1.30 1.34 1.47 1.65 28% <0.001 
Likelihood of undergoing WW/AS 21% 23% 19% 19% 20% -5% 0.17 
Likelihood of referral to radiation 
oncologist 
56% 58% 59% 58% 59% 5% 0.001 
Imaging tests per patient         








































Among patients undergoing WW/AS 
    
  
Months between diagnosis and first 
treatment 
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Among patients receiving surgery 
       
Likelihood of receiving open 
prostatectomy 
19% 18% 16% 19% 19% 0% 0.93 
Likelihood of receiving robot 
prostatectomy 
63% 67% 68% 65% 67% 6% 0.08 
Likelihood of receiving cryosurgery 13% 8% 9% 10% 7% -46% <0.001 
Among patients receiving radiation 
     
  
Spending on radiation ($) 12,719 14,122 15,595 16,244 18,281 44% <0.001 
Likelihood of receiving any EBRT 82% 88% 91% 91% 93% 13% <0.001 
Likelihood of receiving brachytherapy 56% 50% 50% 51% 52% -7% 0.02 
Likelihood of receiving IMRT 74% 80% 84% 84% 87% 18% <0.001 
Likelihood of receiving SBRT 7% 7% 4% 4% 4% -43% 0.001 
Likelihood of receiving proton beam 
therapy 
12% 18% 20% 21% 21% 75% <0.001 
Radiation Oncology           
  
Number of providers 228 228 228 228 228 
  
Number of patients 5810 3272 2388 3305 5644 
  
  
       
Average total spending per patient per 
year ($) 
31,677 34,283 38,129 39,109 45,372 43% <0.001 
Likelihood of undergoing WW/AS 13% 14% 13% 12% 11% -15% 0.02 
Number of Imaging Tests Ordered         
























































Among patients receiving radiation 
       
Spending on radiation ($) 20,915 22,438 26,042 26,350 30,348 45% <0.001 
Likelihood of receiving any EBRT 80% 86% 92% 94% 95% 19% <0.001 
Likelihood of receiving brachytherapy 54% 56% 53% 53% 50% -7% 0.34 
Likelihood of receiving IMRT 71% 78% 84% 87% 89% 25% <0.001 
Likelihood of receiving SBRT 8% 8% 6% 7% 0.1% -88% <0.001 
Likelihood of receiving proton beam 
therapy 
4% 8% 24% 25% 24% 500% <0.001 
Source: Authors’ analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data 2009-2014. 
Notes: Models assigning physicians to quintiles include patient and physician random and fixed effects for time (calendar-quarter of diagnosis), 
patient characteristics (age, race, census tract income, census tract education, disability, dual eligibility, enrollment in part D, Charlson Score), 
disease risk group at diagnosis, treatments (WW/AS, surgery, hormone therapy, and radiation therapy), and Hospital Referral Region (HRR) where 
patients received the plurality of their care. Models predicting total spending, inpatient days, imaging tests, and radiation cost include the 
aforementioned patient, disease, time and geography variables and an indicator for physician quintile. Models predicting likelihood of receiving 
specific treatment modalities also include treatment variables. P-value reported of differences between quintiles 1 and 5. 
Abbreviations: WW/AS = watchful waiting/active surveillance; EBRT = external beam radiation therapy; IMRT = intensity modulated 
radiation therapy; SBRT = stereotactic body radiation therapy; CT = computed tomography; PET = Positron Emission Tomography; 
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Figure 2. Factors that Explain Spending Variation Across Physicians and Facilities
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